198 related articles for article (PubMed ID: 33648909)
21. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
22. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
23. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
[TBL] [Abstract][Full Text] [Related]
24. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
25. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
27. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.
Elder DE; Bastian BC; Cree IA; Massi D; Scolyer RA
Arch Pathol Lab Med; 2020 Apr; 144(4):500-522. PubMed ID: 32057276
[TBL] [Abstract][Full Text] [Related]
28. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
29. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
30. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
31. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Ashida A; Takata M; Murata H; Kido K; Saida T
Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
[TBL] [Abstract][Full Text] [Related]
32. KIT genetic alterations in anorectal melanomas.
Santi R; Simi L; Fucci R; Paglierani M; Pepi M; Pinzani P; Merelli B; Santucci M; Botti G; Urso C; Massi D
J Clin Pathol; 2015 Feb; 68(2):130-4. PubMed ID: 25398993
[TBL] [Abstract][Full Text] [Related]
33. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma.
Abu-Abed S; Pennell N; Petrella T; Wright F; Seth A; Hanna W
J Cutan Med Surg; 2012; 16(2):135-42. PubMed ID: 22513068
[TBL] [Abstract][Full Text] [Related]
34. Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi.
Park E; Yang S; Emley A; DeCarlo K; Richards J; Mahalingam M
Am J Dermatopathol; 2012 Feb; 34(1):41-6. PubMed ID: 22094233
[TBL] [Abstract][Full Text] [Related]
35. Dark homogeneous streak dermoscopic pattern correlating with specific KIT mutations in melanoma.
Sanchez MI; Rabinovitz HS; Oliviero MC; Elgart GW; Perez C; Puig S; Malvehy J; Grichnik JM
JAMA Dermatol; 2014 Jun; 150(6):633-9. PubMed ID: 24695820
[TBL] [Abstract][Full Text] [Related]
36. C-kit expression of melanocytic neoplasm and association with clinicopathological parameters and anatomic locations in Chinese people.
Lin YC; Chang YM; Ho JY; Lin HC; Tsai YM; Chiang CP; Wang WM; Gao HW
Am J Dermatopathol; 2013 Jul; 35(5):569-75. PubMed ID: 23221472
[TBL] [Abstract][Full Text] [Related]
37. C-kit-mutated melanomas: the Chinese experience.
Si L; Guo J
Curr Opin Oncol; 2013 Mar; 25(2):160-5. PubMed ID: 23299198
[TBL] [Abstract][Full Text] [Related]
38. KIT is a frequent target for epigenetic silencing in cutaneous melanoma.
Dahl C; Abildgaard C; Riber-Hansen R; Steiniche T; Lade-Keller J; Guldberg P
J Invest Dermatol; 2015 Feb; 135(2):516-524. PubMed ID: 25178104
[TBL] [Abstract][Full Text] [Related]
39. Mutational profiling of acral melanomas in Korean populations.
Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
[TBL] [Abstract][Full Text] [Related]
40. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.
Rawson RV; Johansson PA; Hayward NK; Waddell N; Patch AM; Lo S; Pearson JV; Thompson JF; Mann GJ; Scolyer RA; Wilmott JS
Lab Invest; 2017 Feb; 97(2):130-145. PubMed ID: 28067894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]